June 3, 2026 · Form 4 insider transaction
SAPIRSTEIN JAMES bought 235,000 shares of Cocrystal Pharma, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 0 days after the transaction.
The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options vest in four equal annual installments, with the first such installment to vest on June 3, 2027, subject in each case to continued employment with the Issuer on the applicable vesting date and subject to potential accelerated vesting upon a Change in Control or termination for Cause, as such terms are defined in the 2025 Equity Incentive Plan.